[
  {
    "ts": "2026-02-09T13:12:28+00:00",
    "headline": "Assessing Hims & Hers Health (HIMS) Valuation After Compounded GLP-1 Launch And Rapid Regulatory Retreat",
    "summary": "Hims & Hers Health (HIMS) has been at the center of attention after launching a discounted compounded semaglutide weight loss pill, then quickly withdrawing it following legal threats from Novo Nordisk and heightened FDA enforcement signals. See our latest analysis for Hims & Hers Health. The regulatory backlash around compounded GLP-1 drugs has hit sentiment hard, with a 30-day share price return of 27.36% and a year to date share price return of 31.10% pointing to fading momentum despite a...",
    "url": "https://finance.yahoo.com/news/assessing-hims-hers-health-hims-131228761.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "a6bedf7f-2602-3738-a918-934d5f2bfbb0",
      "content": {
        "id": "a6bedf7f-2602-3738-a918-934d5f2bfbb0",
        "contentType": "STORY",
        "title": "Assessing Hims & Hers Health (HIMS) Valuation After Compounded GLP-1 Launch And Rapid Regulatory Retreat",
        "description": "",
        "summary": "Hims & Hers Health (HIMS) has been at the center of attention after launching a discounted compounded semaglutide weight loss pill, then quickly withdrawing it following legal threats from Novo Nordisk and heightened FDA enforcement signals. See our latest analysis for Hims & Hers Health. The regulatory backlash around compounded GLP-1 drugs has hit sentiment hard, with a 30-day share price return of 27.36% and a year to date share price return of 31.10% pointing to fading momentum despite a...",
        "pubDate": "2026-02-09T13:12:28Z",
        "displayTime": "2026-02-09T13:12:28Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/0fc6188304291c4515eba03ba128db49",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PPltrydZQyFx0FwyDTKiqQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/0fc6188304291c4515eba03ba128db49.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nAhCdmsJrPs7INBkXmkXpA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/0fc6188304291c4515eba03ba128db49.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/assessing-hims-hers-health-hims-131228761.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/assessing-hims-hers-health-hims-131228761.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "HIMS"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "AMZN"
            },
            {
              "symbol": "COST"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]